Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors.
Darunabir, formerly TMC114, is a new protease inhibitor (PI) under clinical development designed to be active against HIV strains resistant to currently available PI. The virological and immunological response to ritonavir-boosted darunabir was assessed in four heavily antiretroviral-experienced patients who had failed enfuvirtide and two or more previous ritonavir-boosted PI regimens, including tipranavir in one instance. All four patients reached undetectable plasma HIV-RNA levels within 8 weeks of therapy and experienced significant CD4 cell count gains.
Poveda
Eva
E
Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
Blanco
Francisco
F
García-Gascó
Pilar
P
Alcolea
Antonio
A
Briz
Verónica
V
Soriano
Vincent
V
D023241:Antiretroviral Therapy, Highly Active; D000069454:Darunavir; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D012367:RNA, Viral / Q000097:blood; D019438:Ritonavir / Q000627:therapeutic use*; D016879:Salvage Therapy / Q000379:methods; D013449:Sulfonamides / Q000627:therapeutic use*; D017211:Treatment Failure; D019562:Viral Load
D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D013449:Sulfonamides; D019438:Ritonavir; D000069454:Darunavir